These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 33440084)
1. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. Waxman A; Restrepo-Jaramillo R; Thenappan T; Ravichandran A; Engel P; Bajwa A; Allen R; Feldman J; Argula R; Smith P; Rollins K; Deng C; Peterson L; Bell H; Tapson V; Nathan SD N Engl J Med; 2021 Jan; 384(4):325-334. PubMed ID: 33440084 [TBL] [Abstract][Full Text] [Related]
2. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262 [TBL] [Abstract][Full Text] [Related]
3. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475 [TBL] [Abstract][Full Text] [Related]
4. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. Frantz RP; McDevitt S; Walker S J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. Nathan SD; Tapson VF; Elwing J; Rischard F; Mehta J; Shapiro S; Shen E; Deng C; Smith P; Waxman A Am J Respir Crit Care Med; 2022 Jan; 205(2):198-207. PubMed ID: 34767495 [No Abstract] [Full Text] [Related]
7. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
8. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
9. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. Waxman A; Restrepo-Jaramillo R; Thenappan T; Engel P; Bajwa A; Ravichandran A; Feldman J; Hajari Case A; Argula RG; Tapson V; Smith P; Deng C; Shen E; Nathan SD Eur Respir J; 2023 Jun; 61(6):. PubMed ID: 37080567 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N; Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763 [TBL] [Abstract][Full Text] [Related]
12. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF; Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604 [No Abstract] [Full Text] [Related]
13. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098 [TBL] [Abstract][Full Text] [Related]
19. Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease. West N; Smoot K; Patzlaff N; Miceli M; Waxman A Future Cardiol; 2023 Apr; 19(5):229-239. PubMed ID: 37466095 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]